ARA-290
Cibinetide · Innate Repair Receptor agonist
Popular for:Neuropathic pain, diabetic neuropathy, tissue repair without erythropoiesis
22
Total Studies
14
Human Studies
Phase II
Evidence Level
Not Approved
FDA Status
Overview
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) but engineered to activate only the tissue-protective receptor (Innate Repair Receptor) without stimulating red blood cell production. This solves a major problem with EPO — it provides the healing and neuroprotective benefits without the dangerous blood thickening side effects.
Developed by Araim Pharmaceuticals, ARA-290 has been through Phase II clinical trials for diabetic neuropathy, sarcoidosis-associated neuropathic pain, and chronic kidney disease. Results showed significant improvements in small nerve fiber density and neuropathic pain scores.
Mechanism of Action
ARA-290 selectively activates the Innate Repair Receptor (IRR), a heterodimer of EPO receptor and beta common receptor (CD131). Unlike EPO which activates the classical homodimeric EPO receptor (driving erythropoiesis), ARA-290 specifically targets the tissue-protective pathway. IRR activation triggers anti-inflammatory, anti-apoptotic, and tissue repair cascades including upregulation of VEGF, reduction of inflammatory cytokines, and promotion of Schwann cell survival and small nerve fiber regeneration.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
22
Total Studies
14
Human Studies
Not FDA-approved. Phase II completed for multiple indications (Araim Pharmaceuticals). Orphan drug designation for sarcoidosis. Active research compound.
Key Studies / PubMed References
Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways.
Human StudyGhassemi-Barghi N, Ehsanfar Z, Mohammadrezakhani O, et al. · Inflammation · 2023
PMID: 36085231Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Human StudyAl-Onaizi MA, Thériault P, Lecordier S, et al. · Brain, behavior, and immunity · 2022
PMID: 34343617Synthesis and evaluation ofTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region.
In VitroMohtavinejad N, Hajiramezanali M, Akhlaghi M, et al. · Iranian journal of basic medical sciences · 2021
PMID: 35317117A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.
Human StudyLois N, Gardner E, McFarland M, et al. · Journal of clinical medicine · 2020
PMID: 32674280An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.
In VitroShokrzadeh M, Etebari M, Ghassemi-Barghi N · Toxicology in vitro : an international journal published in association with BIBRA · 2020
PMID: 32335150Side Effects & Safety
Known Interactions
No curated interaction entry is live for ARA-290 yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. ARA-290 is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.